FDA Selects First Mental Health AI Company for Review Program
Key Takeaway:
Limbic has entered the FDA's TEMPO program, representing a significant regulatory milestone for integrating artificial intelligence tools into mental health services over the coming years.
What this means for you
A mental health AI company has joined an FDA program to review its technology. Patients should continue standard care while regulatory evaluations and clinical testing proceed.
Citation:
Google News - AI in Healthcare, 2026. Read article →
